Rapid Learning in Times of Crisis: The Opportunities and Challenges of Real-World Data and COVID-19
COVID19 is a new disease where data are being curated in real time presenting unique challenges to both providers and researchers. There have now been some 400,000 deaths from COVID-19 in the US and California is the epicenter of the pandemic at the present time. While vaccines are coming, we will be battling COVID-19 for at least another year or more and there are still many questions about the risk factors and short-term and long-term complications of COVID-19.
Management of patients with COVID19 is uncertain, often based on "real-world data" as few control trials have been conducted to provide reliable evidence for patient care. We need both randomized controlled trials to test new treatments and preventions as well as population data to address whether those treatments are safe and effective in a real world setting. Both clinicians and public health researchers need to fully understand the challenges and opportunities of these two important data paradigms in order to establish the totality of evidence needed to tackle the current COVID-19 health care crisis. There is much to learn about the risk and management of COVID in patients with cancer who are at exceptionally high risk of the infection and serious complications including death from COVID-19. This is the greatest healthcare crisis that the US has ever faced, and we need to learn as much and as rapidly as possible.
The activity content is oriented to address the educational needs of clinicians and researchers.
- Demonstrate key aspects of the analyses of "real-world data".
- Discuss differences in efficacy vs effectiveness vs efficiency.
- Outline key challenges in conducting real-world data analyses.
Virtual Meeting- Zoom
Gary H. Lyman, MD, MPH, FRCP Senior Lead for Healthcare Quality and Policy, Departments of Public Health Sciences and Clinical Research; Fred Hutchinson Cancer Research Center; Professor of Medicine, Public Health and Pharmacy; University of Washington School of Medicine
Nicole M. Kuderer, MD, MS (Equiv.) Medical Director, Advanced Cancer Research Group
Dr. Lyman has indicated that he receives Grant/Research Support from Amgen (Institution) and is a Consultant for BeyondSpring; Bristol Myers Squibb; G1 Therapeutics; Merck; Samsung & TEVA. Dr. Kuderer has indicated she has nothing to disclose.
ACCREDITATION STATEMENT: City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CREDIT DESIGNATION: City of Hope designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The following credit type(s) are being offered for this course:
• AMA PRA Category 1™ 1.0
The following may apply AMA PRA Category 1 Credit™ for license renewal:
Registered Nurses: Nurses may report up to 1.0 credit hours toward the continuing education requirements for license renewal by their state Board of Registered Nurses (BRN). AMA PRA Category 1 Credit™ may be noted on the license renewal application in lieu of a BRN provider number.
Physician Assistants: The National Commission on Certification of Physicians Assistants states that AMA PRA Category 1 Credit™ accredited courses are acceptable for CME requirements for recertification.
- 1.00 AMA PRA Category 1 Credit™City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
City of Hope designates this Rapid Learning in Times of Crisis: The Opportunities and Challenges of Real-World Data and COVID-19 for a maximum of 1.00 AMA PRA Category 1 Credit™ requirements. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.00 Attendance